Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chunsoo | - |
dc.contributor.author | Lee, Kyungsang | - |
dc.contributor.author | Yu, Hyewon | - |
dc.contributor.author | Ryu, Seung-Ho | - |
dc.contributor.author | Moon, Seok Woo | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Jun-Young | - |
dc.contributor.author | Lee, Young Min | - |
dc.contributor.author | Kim, Shin-Gyeom | - |
dc.contributor.author | Kim, Ki Woong | - |
dc.contributor.author | Lee, Dong Woo | - |
dc.contributor.author | Kim, Seong Yoon | - |
dc.contributor.author | Lee, Sang-Yeol | - |
dc.contributor.author | Bae, Jae Nam | - |
dc.contributor.author | Jung, Young-Eun | - |
dc.contributor.author | Kim, Jeong Lan | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.contributor.author | Shin, Il-Seon | - |
dc.contributor.author | Kim, Young Hoon | - |
dc.contributor.author | Kim, Bong Jo | - |
dc.contributor.author | Kang, Hyo Shin | - |
dc.contributor.author | Myung, Woojae | - |
dc.contributor.author | Carroll, Bernard J. | - |
dc.contributor.author | Kim, Doh Kwan | - |
dc.date.accessioned | 2021-09-03T03:39:17Z | - |
dc.date.available | 2021-09-03T03:39:17Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-08 | - |
dc.identifier.issn | 0271-0749 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/82752 | - |
dc.description.abstract | Purpose/Background Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trial, body weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures To clarify whether this finding is consistent across ethnic groups that vary in absolute body mass, we recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10 mg/d for at least 3 months. After screening, we analyzed a final cohort of 166 patients who received donepezil 23 mg/d for 24 weeks to compare the occurrence of treatment-emergent adverse events (TEAEs) between patients with high versus low body mass index (BMI) based on the World Health Organization overweight criteria for Asian populations (23 kg/m(2)). Findings/Results Treatment-emergent adverse events were reported by 79.45% of patients in the lower BMI group and 58.06% of patients in the higher BMI group (odds ratio, 2.79; 95% confidence interval, 1.39-5.63; (2) = 7.58, P = 0.006). In a multivariable survival analysis, the group with lower BMI showed a higher occurrence of TEAEs (hazard ratio, 1.83; 95% confidence interval, 1.25-2.68; P = 0.002). Implications/Conclusions In Korean patients with moderate to severe AD receiving high-dose donepezil over 24 weeks, TEAEs were significantly more common in those with lower BMI (not clinically overweight), especially nausea. This finding may inform clinical practice for Asian patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | 23 MG | - |
dc.subject | TOLERABILITY | - |
dc.subject | MODERATE | - |
dc.subject | DEMENTIA | - |
dc.subject | SAFETY | - |
dc.title | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1097/JCP.0000000000000726 | - |
dc.identifier.scopusid | 2-s2.0-85020255822 | - |
dc.identifier.wosid | 000405329400004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.37, no.4, pp.401 - 404 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.volume | 37 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 401 | - |
dc.citation.endPage | 404 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | 23 MG | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | MODERATE | - |
dc.subject.keywordPlus | DEMENTIA | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | adverse effects | - |
dc.subject.keywordAuthor | Alzheimer disease | - |
dc.subject.keywordAuthor | body mass index | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | donepezil | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.